### CONTENTS

**REVIEW**

1067  Circular RNAs in hepatocellular carcinoma: Recent advances  
*Niu ZS, Wang WH*

1086  Practical considerations for colorectal cancer screening in older adults  
*Gornick D, Kadakuntla A, Trovato A, Stetzer R, Tadros M*

1103  Fibrolamellar hepatocellular carcinoma: A rare but unpleasant event  
*Abdelhamed W, El-Kassas M*

**MINIREVIEWS**

1115  Can dietary flavonoids be useful in the personalized treatment of colorectal cancer?  
*Pereira-Wilson C*

**ORIGINAL ARTICLE**

**Basic Study**

1124  Glutamine deprivation impairs function of infiltrating CD8\(^+\) T cells in hepatocellular carcinoma by inducing mitochondrial damage and apoptosis  
*Wang W, Guo MN, Li N, Pang DQ, Wu JH*

**Retrospective Cohort Study**

1141  Does the addition of Braun anastomosis to Billroth II reconstruction on laparoscopic-assisted distal gastrectomy benefit patients?  
*Li XG, Song QY, Wu D, Li S, Zhang BL, Zhang LY, Guan D, Wang XX, Liu L*

1148  Contemporary, national patterns of surgery after preoperative therapy for stage II/III rectal adenocarcinoma  
*Soriano C, Bahnsen HT, Kaplan JA, Lin B, Moonka R, Pham HT, Kennecke HF, Simianu V*

**Retrospective Study**

1162  Clinicopathological differences, risk factors and prognostic scores for western patients with intestinal and diffuse-type gastric cancer  
*Díaz del Arco C, Estrada Muñoz L, Ortega Medina L, Molina Roldán E, Cerón Nieto MÁ, García Gómez de las Heras S, Fernández Aceñero MJ*

**Observational Study**

1175  Characterizing the patient experience during neoadjuvant therapy for pancreatic ductal adenocarcinoma: A qualitative study  
## Contents

**World Journal of Gastrointestinal Oncology**

**Monthly Volume 14 Number 6 June 15, 2022**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1187</td>
<td>Randomized Controlled Trial</td>
<td>Zhou XD, Wei HG, Ai FL</td>
</tr>
<tr>
<td>1210</td>
<td>LETTER TO THE EDITOR</td>
<td>Abushukair HM, Saeed A</td>
</tr>
<tr>
<td>1213</td>
<td></td>
<td>Abushukair HM, Zaitoun SM, Saeed A</td>
</tr>
<tr>
<td>1216</td>
<td>CORRECTION</td>
<td>Li YS, Zou Y, Dai DQ</td>
</tr>
</tbody>
</table>

**Randomized Controlled Trial**

**Biofeedback therapy combined with Baduanjin on quality of life and gastrointestinal hormone level in patients with colorectal cancer**  
Zhou XD, Wei HG, Ai FL

**META-ANALYSIS**

**Does chronic kidney disease affect the complications and prognosis of patients after primary colorectal cancer surgery?**  
Liu XY, Zhang B, Cheng YX, Tao W, Yuan C, Wei ZQ, Peng D

**LETTER TO THE EDITOR**

**Hepatocellular carcinoma and immunotherapy: Beyond immune checkpoint inhibitors**  
Abushukair HM, Saeed A

**Insight on BRAF\textsuperscript{V600E} mutated colorectal cancer immune microenvironment**  
Abushukair HM, Zaitoun SM, Saeed A

**CORRECTION**

**Correction to "MicroRNA-320a suppresses tumor progression by targeting PBX3 in gastric cancer and is downregulated by DNA methylation"**  
Li YS, Zou Y, Dai DQ
ABOUT COVER
Editorial Board Member of World Journal of Gastrointestinal Oncology, Tamás Micsik, MD, PhD, Assistant Professor, The First Department of Pathology and Experimental Cancer Research, Semmelweis University Budapest, Budapest h-1085, Hungary. micsikt@gmail.com

AIMS AND SCOPE
The primary aim of World Journal of Gastrointestinal Oncology (WJGO, World J Gastrointest Oncol) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, etc.

INDEXING/ABSTRACTING
The WJGO is now indexed in Science Citation Index Expanded (also known as SciSearch®), PubMed, PubMed Central, and Scopus. The 2021 edition of Journal Citation Reports® cites the 2020 impact factor (IF) for WJGO as 3.393; IF without journal self cites: 3.333; 5-year IF: 3.519; Journal Citation Indicator: 0.5; Ranking: 163 among 242 journals in oncology; Quartile category: Q3; Ranking: 60 among 92 journals in gastroenterology and hepatology; and Quartile category: Q3. The WJGO’s CiteScore for 2020 is 3.3 and Scopus CiteScore rank 2020: Gastroenterology is 70/136.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Ying-Yi Yuan; Production Department Director: Xiang Li; Editorial Office Director: Ya-Juan Ma.

NAME OF JOURNAL
World Journal of Gastrointestinal Oncology

ISSN
ISSN 1948-5204 (online)

LAUNCH DATE
February 15, 2009

FREQUENCY
Monthly

EDITORS-IN-CHIEF
Monjur Ahmed, Florin Burada

EDITORIAL BOARD MEMBERS

PUBLICATION DATE
June 15, 2022

COPYRIGHT
© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/GerInfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/GerInfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/GerInfo/239

ONLINE SUBMISSION
https://www.f6publishing.com
Correction to "MicroRNA-320a suppresses tumor progression by targeting PBX3 in gastric cancer and is downregulated by DNA methylation"

Yong-Shuang Li, Ying Zou, Dong-Qiu Dai

Abstract

We rechecked the original data of Figure 3, Part.B, and found that 0 h group in the BGC-823 cell wound scratch assay was misapplied. Therefore, we are writing to apply for the modification of Figure 3, Part.B.

Key Words: Correction; Gastric cancer; miRNA-320a; DNA methylation

Core Tip: This is a correction to "MicroRNA-320a suppresses tumor progression by targeting PBX3 in gastric cancer and is downregulated by DNA methylation".

Citation: Li YS, Zou Y, Dai DQ. Correction to "MicroRNA-320a suppresses tumor progression by targeting PBX3 in gastric cancer and is downregulated by DNA methylation". World J Gastrointest Oncol 2022; 14(6): 1216-1217

DOI: https://dx.doi.org/10.4251/wjgo.v14.i6.1216

CORRECTION

Correction to: Li YS, Zou Y, Dai DQ. MicroRNA-320a suppresses tumor progression by targeting PBX3 in gastric cancer and is downregulated by DNA methylation. World J Gastrointest Oncol 2019; 11(10): 842-856 PMID: 31662823 DOI: 10.4251/wjgo.v11.i10.842.
We recently read our manuscript published in the *World Journal of Gastrointestinal Oncology* (Manuscript NO: 48527, DOI: 10.4251/wjgo.v11.i10.842), we have carefully rechecked the original data of Figure 3, Part.B, and found that 0 h group in the BGC-823 cell wound scratch assay was misapplied. Therefore, we are writing to apply for the modification of Figure 3, Part.B. The revised images are shown in this Correction (Figure 1). We feel deeply sorry for this mistake during the proofreading process. This correction does not alter any interpretation of the results or conclusion of this study[1]. We apologize for any inconvenience caused by this mistake.

Figure 1 Part.B. Overexpression of miR-320a suppressed gastric cancer cell migration and invasion.

**FOOTNOTES**

**Author contributions:** Li YS and Dai DQ submitted the final manuscript and all authors read and approved the final version.

**Conflict-of-interest statement:** All authors declare that they have no conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: [https://creativecommons.org/Licenses/by-nc/4.0/](https://creativecommons.org/Licenses/by-nc/4.0/)

**Country/Territory of origin:** China

**ORCID number:** Yong-Shuang Li 0000-0002-0474-853X; Ying Zou 0000-0003-2067-0995; Dong-Qiu Dai 0000-0002-1154-3276.

**S-Editor:** Wang LL
**L-Editor:** A
**P-Editor:** Wang LL

**REFERENCES**

1. Li YS, Zou Y, Dai DQ. MicroRNA-320a suppresses tumor progression by targeting PBX3 in gastric cancer and is downregulated by DNA methylation. *World J Gastrointest Oncol* 2019; 11: 842-856 [PMID: 31662823 DOI: 10.4251/wjgo.v11.i10.842]